The Affordable Care Act was signed into law 9 years ago and created a biosimilars market in the United States, but what could happen if the Trump administration is successful in persuading the Fifth Circuit Court of Appeals to affirm a lower court ruling that the law is invalid?
Will the Trump administration’s decision to say it would approve a possible federal appeals court ruling to completely overturn the Affordable Care Act (ACA) and its hundreds of provisions for healthcare and pharmaceuticals—including the creation of a biosimilars market in the United States—really come to pass?
Last December, US District Judge Reed O’Connor ruled that the ACA is unconstitutional because the president signed a tax plan removing the penalty for not having insurance. Under previous Attorney General Jeff Sessions, the Department of Justice (DOJ) said that while the law’s protections for people with pre-existing conditions should be struck down, the rest of the law, including the expansion of Medicaid, should survive.
Three DOJ attorneys, who now work under William Barr, sent a 2-sentence letter late Monday saying that the administration believes O’Connor’s ruling should be affirmed and that they will be filing a brief on the issue.
The ACA, when it was signed into law 9 years ago this past Saturday, created a biosimilars market in the United States through the Biologics Price Competition and Innovation Act (BPCIA), which provides the basis for the biosimilar regulatory pathway.
The BPCIA provides the framework under which biosimilars and interchangeable biologics can be approved by the FDA.
A coalition of Democratic-led states, led by California, is appealing O’Connor’s decision to the Fifth Circuit Court of Appeals. The decision in the case, Texas v Azar, was made in favor of the 20 Republican-led states that sued the federal government over the constitutionality of the ACA.
For now, the administration is not saying what it would try to implement in the ACA’s place. That omission could come into play in future court rulings, said Ha Kung Wong, JD, a partner at Venble LLP, in an email to The Center for Biosimilars®.
“I think that not having a transition plan or alternative in place for healthcare would make a decision by the Fifth Circuit to affirm the District Court unlikely, at least from a practical impact position, particularly since the legal position supporting complete invalidation of the ACA is debatable,” Wong wrote. “If the Fifth Circuit does affirm the District Court though, I’d expect the Supreme Court to pick up the appeal since they’ve previously upheld the ACA, and they’d want to consider the legal issue more carefully before allowing for the inevitable practical impact on available healthcare.”
But, he said, if the lower court’s decision is reversed, he would expect the Supreme Court to stay out of the matter for now and let it continue to play out in the lower court.
Regarding the specific impact on the BPCIA and biosimilars litigation if the ACA is repealed, Wong said, “I think the BPCIA will be subject of significant debate as it looks to be re-passed in Congress, particularly in light of how its applicability has been interpreted by the courts. Though since the [information exchange] process is still considered optional by the courts, [the ruling] might not have an immediate impact on biosimilars litigation."
Wong said last year that most parties, generally speaking, were still deciding whether to engage in the patent dance in light of the ruling in Sandoz v Amgen.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.